These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18376229)

  • 1. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
    Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of matrix metaloproteinase and tissue inhibitors in ovarian tumors].
    Cai W; Song JD
    Ai Zheng; 2002 Jan; 21(1):91-4. PubMed ID: 12500407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer.
    Edler D; Hallström M; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    Clin Cancer Res; 2000 Apr; 6(4):1378-84. PubMed ID: 10778966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
    Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
    Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
    Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
    Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
    Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
    Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer.
    Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
    Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
    Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
    Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative borderline elevated CEA predicts for earlier relapse in patients with rectal cancer receiving adjuvant postoperative therapy.
    Dawson LA; Franssen E; Davey P
    Cancer J Sci Am; 1999; 5(6):374-9. PubMed ID: 10606480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
    Guo W; Chen G; Zhu C; Wang H
    Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
    Li L; Zhang S; Lin H; Lin JY
    Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
    Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
    J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
    Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
    Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
    Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.
    Massi D; Franchi A; Ketabchi S; Paglierani M; Pimpinelli N; Santucci M
    Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas.
    Ondruschka C; Buhtz P; Motsch C; Freigang B; Schneider-Stock R; Roessner A; Boltze C
    Pathol Res Pract; 2002; 198(8):509-15. PubMed ID: 12389993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.